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Genome wide association studies need validation 
The unexplained variability in drug effects, desired and undesired alike, remains a challenge in 
medical oncology. Individualized treatment aims at eliminating both unnecessary adverse drug 
reactions and unnecessary treatment. Taxanes are of undisputed benefit in ovarian cancer and a 
wide range of other solid tumors [1]. Serious and sometimes irreversible neuropathy and bone 
marrow suppression affects a significant proportion of patients causing treatment delay and 
decreased quality of life of the patients. A huge effort has been put in identifying single 
nucleotide polymorphisms (SNPs) as predictors of toxicity, but successes with clinical 
application are yet to be seen. The recent advances in cost effective high throughput genotyping 
has led to more frequent use of genome wide association studies (GWAS) instead of the 
hypothesis driven candidate gene studies. GWASs are performed without a hypothesis and while 
the method involves correction for multiple testing (Bonferroni or similar), a corresponding 
adjustment of effects is usually not implemented. It is therefore often necessary to validate the 
results in other cohorts and to perform functional studies in order to consolidate the findings [2]. 
Recently, Schneider and coworkers presented the preliminary results of a GWAS performed in 
2204 breast cancer patients of mixed ethnicity treated with weekly paclitaxel in a phase 3 trial [3] 
(NCT00433511). The primary endpoint was time to grade 2-4 neuropathy (Common toxicity 
Criteria) and at the interim analysis 613 patients had grade 2-4 neuropathy (28%). Promising 
gene-variant candidates included RWDD3 (rs2296308) and TECTA (rs1829). RWDD3 showed an 
allele dose dependent association with time to neuropathy with a hazard ratio of 1.5 per allele; 
neuropathy frequencies were 27% (wildtype/wildtype), 40% (wt/variant) and 60% (var/var) 
respectively, P= 8.5x10-8. TECTA showed that homozygocity for the variant genotype was 
associated with a neuropathy hazard ratio of 2.07 compared to other genotypes, P=3.15x10-7; 
neuropathy frequencies were 29%, 30% and 55% for wt/wt, wt/var and var/var, respectively. 
The aim of this study was to replicate the reported association between the RWDD3 (rs2296308) 
and TECTA (rs1829) and time to neuropathy.  
2 
 
Patients and Methods 
We retrospectively included patients from 3 cohorts of Scandinavian women with ovarian cancer 
treated with paclitaxel 175 mg/m2 ,q3w and carboplatin AUC 5-6 mg*min/mL. The cohorts have 
previously been described in detail [4-6]. Briefly, patients were included if DNA was available 
along with time to neuropathy data. The study was approved by ethics committees in Denmark 
and Sweden, and was carried out in accordance with the Helsinki declaration. 
RWDD3 (rs2296308) and TECTA (rs1829) genotyping was performed using TaqMan® SNP 
genotyping assays (Applied Biosystems, Foster City, CA) on a StepOne Plus machine (Applied 
Biosystems, Foster City, CA). 
Univariate analyses of the genotypes were carried out by fitting a Cox model under the 
assumption of proportional hazards. A likelihood-ratio test was used to formally test if the 
estimated hazard ratios were different to the reported values. Statistical analyses were carried out 
using STATA10, 2009, StataCorp, TX, USA.  
Results 
In total 241 patients were included in the study. In four cases the genotype could not be obtained 
(two for each gene). No departure from Hardy-Weinberg equilibrium was observed. Neuropathy 
grade 2 or worse was registered for 65 patients (27%). See Table 1 for neuropathy distribution 
across genotypes. Neuropathy hazard ratios for RWDD3 (per allele) and TECTA (wt/wt+wt/var 
vs var/var) were 0.95 [95% c.i. 0.57-1.58], P-value 0.84 (see Figure 1) and 0.21 [95% c.i. 0.03-
1.53], P-value 0.12 (see Figure 2), respectively. For TECTA using the trend model (wt/wt vs 
wt/var vs var/var) the neuropathy hazard ratio was 0.98 [95% c.i. 0.65-1.46], P-value 0.91. P-
values for the likelihood-ratio test of equality between obtained hazard ratios and reported ones 
were 0.0628 and 0.0007 for RWDD3 and TECTA, respectively.  
Discussion 
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The results of this replication study clearly indicates that the association between the SNPs 
rs2296308 in RWDD3 and rs1829 in the intron of TECTA and time-to-neuropathy in paclitaxel 
treatment reported by Schneider et al was not found in our population. For RWDD3 the hazard 
ratio was 0.95 compared to the hazard ratio of 1.5 in the initial report. Because the upper limit of 
the 95% confidence interval in our study was 1.58, and because the P-value for the likelihood-
ratio test was only close to significant (0.0628) we cannot decidedly rule out an association of the 
magnitude reported by Schneider et al, but it seems very unlikely. For TECTA the hazard ratio 
was 0.21 compared to 2.07 in the initial report. Interestingly, our data suggests a trend towards a 
protective effect (P-value 0.12) of the var/var genotype compared to other genotypes; ie. in 
contrast to the initial report. The likelihood-ratio test was highly significant (P-value 0.0007) 
suggesting that the true hazard ratio is different from the reported value of 2.07. 
Little is known about RWDD3 and TECTA but they have been implied to play a role in 
neurosensoric hear loss and cellular stress [7] which makes them plausible candidates for 
neuropathy susceptibility, but more studies, including functional studies are clearly warranted. 
Dogmatically, three possible reasons for a failure to replicate should be considered: a) Type 1 
error in our study, i.e. falsely rejecting the hypotheses that the true effects coincide with the 
reported ones. However, the confidence intervals for the hazard ratios excluded or nearly 
excluded the originally reported hazard ratios. This suggests that a type 1 error is unlikely. 
However, due to the modest size of our study population (241 vs 2204 in the initial report) and 
because of the unexpected protective effect of TECTA further validation studies are warranted. b) 
Overestimation in the original report, i.e. that the observed correlation between SNPs and time to 
neuropathy was mainly a chance finding. The risk of overestimation is imminent to any GWAS, 
as no corrections are made. Hence our result may just illustrate the need for validation studies. c) 
That the two studied populations differ in ways that invalidates the comparison. Notably, 
paclitaxel was administered every week for 12 weeks in the primary study as opposed to every 
third week for 18-27 weeks in our study. Paclitaxel given every third week with higher paclitaxel 
dose than weekly paclitaxel possible has different neuropathic potential and the two studies also 
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differ with regard to adjuvant chemotherapy. In spite of different regimen the prevalence of grade 
2-4 neuropathy was remarkably similar: 27% in this study compared to 28% in the primary 
study. The primary study found an effect of ethnicity and age on time to neuropathy. Our 
population was exclusively Caucasian and age was not a significant covariate in our population; 
hazard ratio 1.02 [95% c.i. 0.99-1.04], P-value 0.19. For completeness age was included in the 
Cox model, but changes were insignificant (data not shown).  
In conclusion, this study clearly failed to replicate a GWAS reporting an association between the 
two SNPs rs2296308 in RWDD3 and rs1829 in the intron of TECTA and time to neuropathy in 
patients treated with paclitaxel. Unexpectedly, the TECTA var/var genotype suggested protection 
rather than susceptibility to neuropathy, but this finding itself warrants replication. 
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 Table 1. Observed frequencies of patients with neuropathy grade 2+ by RWDD3 and TECTA 
genotype 
Genotype Neuropathy  
grade 2+ 
Neuropathy  
grade 0-1 
Total 
RWDD3 (rs2296308)    
   GG (wt/wt) 48 127 175 
   GT (wt/var) 15 44  59 
   TT (var/var) 1  4  5 
TECTA (rs1829)    
   CC (wt(wt) 32 101  133 
   CT (wt/var) 32 62  94 
   TT (var/var) 1 11  12 
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Figure 1. Time to neuropathy grade 2+ by RWDD3 genotype for 239 patients treated with 
paclitaxel 
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Figure 2. Time to neuropathy grade 2+ by TECTA genotype for 239 patients treated with 
paclitaxel 
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